General Information of Drug (ID: DM8N79M)

Drug Name
(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine Drug Info
Synonyms CHEMBL76457; (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine; 2-(2-Bromoanilino)-1H-imidazole; BDBM50055833
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10490084
TTD Drug ID
DM8N79M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [3]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [4]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [5]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [6]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [7]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [8]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [9]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [10]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [12]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [13]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [14]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [15]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [16]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [17]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [18]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [19]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [20]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methamphetamine DMPM4SK Anxiety Approved [21]
Propericiazine DME9JNL Psychiatric disorder 6E8Z Approved [22]
Methoxamine DMF5XQH Hypertension BA00-BA04 Approved [23]
Phendimetrazine DM6TS1N Obesity 5B81 Approved [24]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [16]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [25]
Sunepitron DM6M8ZX N. A. N. A. Discontinued in Phase 3 [26]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [18]
SOU-001 DMPAEK5 Urinary incontinence MF50.2 Discontinued in Phase 2 [27]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [28]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [29]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [30]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [31]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [32]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [33]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [34]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [35]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [16]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [36]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [37]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [38]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [38]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [39]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [40]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [41]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [42]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [16]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [37]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [37]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [25]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1B (ADRA1B) TTBRKXS ADA1B_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Inhibitor [1]

References

1 Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
2 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
3 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
5 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
6 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
7 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
8 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
9 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
10 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
11 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
12 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
13 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
14 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
15 Clinical pipeline report, company report or official report of Klus Pharma
16 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
19 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
20 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
21 Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
22 Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
23 Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
24 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
25 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
26 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
27 Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
28 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
29 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
30 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
31 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
32 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
33 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
34 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
35 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
36 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
37 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
38 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
39 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
40 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
41 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
42 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.